Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 335

1.

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T.

AIDS. 2001 Jan 5;15(1):71-5.

PMID:
11192870
2.

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T.

Clin Pharmacol Ther. 2003 Jan;73(1):20-30.

PMID:
12545140
3.

Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.

Langmann P, Weissbrich B, Desch S, Väth T, Schirmer D, Zilly M, Klinker H.

Eur J Med Res. 2002 Jul 24;7(7):309-14.

PMID:
12176680
4.

Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects.

Ståhle L, Moberg L, Svensson JO, Sönnerborg A.

Ther Drug Monit. 2004 Jun;26(3):267-70.

PMID:
15167626
5.

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

Gutiérrez F, Navarro A, Padilla S, Antón R, Masiá M, Borrás J, Martín-Hidalgo A.

Clin Infect Dis. 2005 Dec 1;41(11):1648-53. Epub 2005 Oct 19.

6.

Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.

Poeta J, Linden R, Antunes MV, Real L, Menezes AM, Ribeiro JP, Sprinz E.

J Antimicrob Chemother. 2011 Nov;66(11):2601-4. doi: 10.1093/jac/dkr360. Epub 2011 Sep 2.

7.

[Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia].

Martorell M, López RM, Ribera E, Ruiz I, Tural C, Puig L, Monterde J.

Enferm Infecc Microbiol Clin. 2005 Jun-Jul;23(6):349-52. Spanish.

PMID:
15970167
8.

Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.

Funk MB, Notheis G, Schuster T, Elanjkal Z, von Hentig N, Stürmer M, Linde R, Dunsch D, Königs C, Wintergerst U, Kreuz W.

Eur J Med Res. 2005 Dec 7;10(12):503-8.

PMID:
16356864
9.

Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.

Pereira SA, Branco T, Caixas U, Côrte-Real RM, Germano I, Lampreia F, Monteiro EC.

Ther Drug Monit. 2008 Feb;30(1):60-6. doi: 10.1097/FTD.0b013e318160ce76.

PMID:
18223464
10.
11.

Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.

Piketty C, Race E, Castiel P, Belec L, Peytavin G, Si-Mohamed A, Gonzalez-Canali G, Weiss L, Clavel F, Kazatchkine MD.

AIDS. 1999 Jul 30;13(11):F71-7.

PMID:
10449277
12.

Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study.

Friedl AC, Ledergerber B, Flepp M, Hirschel B, Telenti A, Furrer H, Bucher HC, Bernasconi E, Weber R; Swiss Cohort Study.

AIDS. 2001 Sep 28;15(14):1793-800.

PMID:
11579241
13.

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.

Manfredi R, Calza L, Chiodo F.

J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):492-502.

PMID:
15021314
14.

Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations.

González de Requena D, Gallego O, Corral A, Jiménez-Nácher I, Soriano V.

AIDS. 2004 Oct 21;18(15):2091-4.

PMID:
15577634
15.

Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens.

Fumaz CR, Tuldrà A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, Negredo E, Romeu J, Sirera G, Tural C, Clotet B.

J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):244-53.

PMID:
11873073
16.
17.

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.

Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, Bower M, Johnson MA, Gazzard BG.

AIDS. 2002 Jan 4;16(1):53-61.

PMID:
11741163
18.

Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.

Allavena C, Ferré V, Brunet-François C, Delfraissy JF, Lafeuillade A, Valantin MA, Bentata M, Michelet C, Poizot-Martin I, Dailly E, Launay O, Raffi F; Bitherapy Kaletra-Sustiva Study Group.

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):300-6.

PMID:
15980689
19.

Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs.

Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, Albrecht MA; ACTG 364 Study Team.

AIDS. 2003 Apr 11;17(6):821-30.

PMID:
12660529
20.

Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Dahri K, Ensom MH.

Clin Pharmacokinet. 2007;46(2):109-32. Review.

PMID:
17253884
Items per page

Supplemental Content

Write to the Help Desk